Pirfenidone-d<sub>5</sub>

Pirfenidone-d5

CAT N°: 26452
Price:

From 159.00 135.15

Pirfenidone-d5 is intended for use as an internal standard for the quantification of pirfenidone (Item No. 13986) by GC- or LC-MS. Pirfenidone is an orally bioavailable pyridone derivative with antifibrotic, anti-inflammatory, and antioxidant activities.{42405,42406,42407,21821,21616} It inhibits TGF-?1-stimulated increases in collagen type I, fibronectin, and Hsp47 expression in A549 lung cancer cells in a concentration-dependent manner.{21821} Pirfenidone (300 mg/kg per day) inhibits fibrosis and inhibits increases in collagen content, fibrocyte pool size, and the levels of chemokines CCL2 and CCL12 in lung in a mouse model of pulmonary fibrosis induced by bleomycin (Item No. 13877).{42406} In a mouse model of non-alcoholic steatohepatitis (NASH), pirfenidone inhibits fibrosis and increases in hepatocyte apoptosis, lobular inflammation, and hepatic expression of the fibrosis-related genes Col1a1, Timp1, Tgfb1, Pdgfb, and Fgf2 when administered at a dose of 280 mg/kg but has no effect on steatosis.{42405} Pirfenidone also inhibits NADPH-dependent lipid peroxidation in sheep liver microsomes and scavenges hydroxyl radicals (IC50s = ~6 and ~2.5 mM, respectively).{42407} Formulations containing pirfenidone have been used in the treatment of idiopathic pulmonary fibrosis.

We also advise you

TAF 10 Peptide

TAF 10 Peptide

TAF10 is one of many protein factors or coactivators associated with RNA polymerase II activity.{16903} One vial of this peptide...

€191.00
View